🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "huge turning point" in the fight against drug-resistant strains of the infection, according to scientists.

A Global Public Health Issue

The sexually transmitted infection are on the rise around the world, with figures suggesting in excess of 82 million instances per year. Particularly high rates are reported in Africa and nations within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary development in the context of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted treatment choices currently available.”

Public health authorities are particularly alarmed about the rise in treatment-resistant strains. The global health body has designated it as a "critical concern". Ongoing monitoring showed that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Secure Clearance

Zoliflodacin, alternatively called a brand name, was cleared by the US FDA in December for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers believe that focused deployment of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GSK, gained clearance in the same week. This treatment, which is also used to treat UTIs, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This milestone signifies a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Clinical Trial Results and Global Access

As per results released by a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the typical regimen, which uses two antibiotics. The study included over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the ability to make available and distribute the drug in many developing nations.

Clinicians on the front lines have expressed positive views. The availability of a single-dose, oral treatment like this is hailed as a "revolutionary step" for gonorrhoea control. This is viewed as crucial to alleviate the strain of the illness for people and to stop the proliferation of extremely resistant gonorrhoea around the world.